According to the latest NCCN Guidelines for NSCLC (https://www.nccn.org), ROS1 rearrangement and BRAF V600E mutation were newly incorporated into initial gene testing, and the recommendation for PD-L1 detection was strengthened from 2A to 1. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.